Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 1
2000 1
2002 2
2003 2
2004 2
2005 1
2006 2
2007 3
2008 3
2009 4
2010 3
2012 1
2013 2
2014 2
2015 4
2016 2
2019 1
2021 1
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

32 results
Results by year
Filters applied: . Clear all
Page 1
IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
Krueger JG, Wharton KA Jr, Schlitt T, Suprun M, Torene RI, Jiang X, Wang CQ, Fuentes-Duculan J, Hartmann N, Peters T, Koroleva I, Hillenbrand R, Letzkus M, Yu X, Li Y, Glueck A, Hasselberg A, Flannery B, Suárez-Fariñas M, Hueber W. Krueger JG, et al. Among authors: hueber w. J Allergy Clin Immunol. 2019 Sep;144(3):750-763. doi: 10.1016/j.jaci.2019.04.029. Epub 2019 May 24. J Allergy Clin Immunol. 2019. PMID: 31129129 Free article. Clinical Trial.
Reply.
Hueber W, Hassfeld W, Smolen JS, Steiner G. Hueber W, et al. Rheumatology (Oxford). 2000 Feb;39(2):218. doi: 10.1093/rheumatology/39.2.218. Rheumatology (Oxford). 2000. PMID: 10725081 No abstract available.
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP; Secukinumab in Crohn's Disease Study Group. Hueber W, et al. Gut. 2012 Dec;61(12):1693-700. doi: 10.1136/gutjnl-2011-301668. Epub 2012 May 17. Gut. 2012. PMID: 22595313 Free PMC article. Clinical Trial.
Proteomic biomarkers for autoimmune disease.
Hueber W, Robinson WH. Hueber W, et al. Proteomics. 2006 Jul;6(14):4100-5. doi: 10.1002/pmic.200600017. Proteomics. 2006. PMID: 16786488 Review.
Secukinumab for ankylosing spondylitis--authors' reply.
Baeten D, Hueber W. Baeten D, et al. Among authors: hueber w. Lancet. 2014 Mar 1;383(9919):780-1. doi: 10.1016/S0140-6736(14)60399-8. Lancet. 2014. PMID: 24581662 No abstract available.
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ, Fox R, Dörner T, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki JN, Sopala MA, Luo WL, Hueber W. Bowman SJ, et al. Among authors: hueber w. Lancet. 2022 Jan 8;399(10320):161-171. doi: 10.1016/S0140-6736(21)02251-0. Epub 2021 Nov 30. Lancet. 2022. PMID: 34861168 Clinical Trial.
Autoimmunity against fibrinogen mediates inflammatory arthritis in mice.
Ho PP, Lee LY, Zhao X, Tomooka BH, Paniagua RT, Sharpe O, BenBarak MJ, Chandra PE, Hueber W, Steinman L, Robinson WH. Ho PP, et al. Among authors: hueber w. J Immunol. 2010 Jan 1;184(1):379-90. doi: 10.4049/jimmunol.0901639. Epub 2009 Nov 30. J Immunol. 2010. PMID: 19949094 Free PMC article.
Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.
Reich K, Papp KA, Matheson RT, Tu JH, Bissonnette R, Bourcier M, Gratton D, Kunynetz RA, Poulin Y, Rosoph LA, Stingl G, Bauer WM, Salter JM, Falk TM, Blödorn-Schlicht NA, Hueber W, Sommer U, Schumacher MM, Peters T, Kriehuber E, Lee DM, Wieczorek GA, Kolbinger F, Bleul CC. Reich K, et al. Among authors: hueber w. Exp Dermatol. 2015 Jul;24(7):529-35. doi: 10.1111/exd.12710. Epub 2015 May 8. Exp Dermatol. 2015. PMID: 25828362 Free PMC article. Clinical Trial.
32 results